U.S. health regulators informed senior executives at Merck, Sanofi and AstraZeneca last week that their approved protective ...

FDA turns up the heat: Federal regulators are requesting more safety information from drugmakers on products meant to protect ...

Among adults older adults, a respiratory syncytial virus (RSV) infection increases the risk of cardiovascular events over the ...

GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) ...

The FDA reportedly told drugmakers that approved monoclonal antibodies to protect infants against respiratory syncytial virus ...

As an FDA official said that the agency has evidence that links COVID vaccines to the deaths of at least 10 children, the U.S ...

In a new study, adults 45 and up who got this seasonal virus had a higher risk of major heart issues, especially in the first ...

Respiratory syncytial virus, commonly known as RSV, is often associated with cold-like symptoms in young children.

Researchers evaluated the real-world effectiveness of nirsevimab in preventing ICU admission and acute respiratory failure associated with RSV among infants.

Early-life viral infection programs immune cells to hijack allergy-associated maternal antibodies, driving allergy risk later ...

Recovering from respiratory syncytial virus often doesn't end when it's time to leave the hospital, even for younger adults.

An infection with respiratory syncytial virus (RSV) typically affects infants much harder than adults. While adults usually ...